Single-agent Dasatinib May Be Active in Undifferentiated Pleomorphic Sarcoma

Share this content:
Dasatinib may have activity in patients with undifferentiated pleomorphic sarcoma but is not an effective monotherapy for other sarcoma types.
Dasatinib may have activity in patients with undifferentiated pleomorphic sarcoma but is not an effective monotherapy for other sarcoma types.

Dasatinib may have activity in patients with undifferentiated pleomorphic sarcoma but it is inactive as monotherapy in other sarcoma types, including leiomyosarcoma and rhabdomyosarcoma.1

Because dasatinib exhibited activity in preclinical models of sarcoma, researchers at the Sarcoma Alliance for Research through Collaboration (SARC) sought to evaluate the activity of single-agent dasatinib in patients with advanced sarcoma.

For the multicenter, phase 2 trial, researchers enrolled a total of 200 patients and were assigned to 1 of 7 different cohorts based on sarcoma subtype. All patients received dasatinib twice daily and were assessed by imaging every 8 weeks.

Due to a low estimated clinical benefit rate in 5 cohorts, the investigators stopped accrual in those cohorts early. Results showed that 8 of 42 evaluable patients with undifferentiated pleomorphic sarcoma and 6 of 47 evaluable patients with leiomyosarcoma demonstrated a clinical benefit. Researchers found that the probability that the clinical benefit rate was 25% or higher was 0.10 in the undifferentiated pleomorphic sarcoma group, but only 0.008 in the leiomyosarcoma group.

Median progression-free survival ranged from 0.9 months in patients with rhabdomyosarcoma to 2.2 months in patients with leiomyosarcoma, and the median overall survival was 8.6 months.

In regard to safety, 11% of patients experienced treatment-related serious adverse events with 36% of patients requiring dose reduction for toxicity. The most frequent adverse events were constitutional, gastrointestinal, and respiratory.

Reference

  1. Schuetza SM, Wathen JK, Lucas DR, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma [published online ahead of print December 28, 2015]. Cancer. doi: 10.1002/cncr.29858.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs